FWP
REGN icon

Family Wealth Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Family Wealth Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-375
Closed -$290K – 124
2026
Q1 		$290K Buy
375
+48
+15% +$36.7K 0.1% 82
2025
Q4 		$252K Buy
+327
New +$222K 0.09% 76

Other funds holding REGN

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
MCI
McDonald Capital Investors Orinda, California $1.37B AUM 1.88% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

Family Wealth Partners's REGN Position: Q2 2026 in Review

Family Wealth Partners sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 375 shares — an estimated $290K sold.

Family Wealth Partners first reported a position in REGN in Q4 2025 and held it in 2 quarters. The position peaked at $290K in Q1 2026. 518 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Family Wealth Partners reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Family Wealth Partners sold 375 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $290K.
  • Family Wealth Partners first reported a position in Regeneron Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Family Wealth Partners's Regeneron Pharmaceuticals position peaked at $290K in Q1 2026.
  • 518 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Family Wealth Partners's 13F filing for Q2 2026, filed 10 Jul 2026.